Glyphward

Inavolisib (Itovebi; GDC-0077; CAS 2244678-91-7): NIOSH HD Category 1 SEVENTY-FIRST Mechanism Class [FIRST PIK3CA MUTANT-SELECTIVE FUNCTIONAL DEGRADER-INHIBITOR EVER FDA APPROVED (NDA 218883; October 10, 2024; PIK3CA H1047R Kinase-Domain Activation-Loop Mutation + E545K Helical-Domain Mutation >5× Mutant vs WT PI3Kα Selectivity; Proteasomal Degradation of Mutant PIK3CA Protein Sparing Wild-Type; INAVO120 PFS HR 0.43 15.0 vs 7.3 months; ORR 58.4%; OS HR 0.64; HR+/HER2− mBC; Genentech/Roche)] + Triplet inavolisib 9 mg QD + palbociclib 125 mg QD (21d/7d) + fulvestrant 500 mg Q4W (First PI3Kα + CDK4/6i + ET Triplet Ever FDA Approved) + rCobas PIK3CA ctDNA Liquid Biopsy Companion Diagnostic; Genentech Inc. South San Francisco CA Cority ÷10; Roche Pharma Branchburg NJ VelocityEHS ÷10; Dana-Farber Cancer Institute Boston MA EHS Insight ÷10; Glyphward Threshold 22; 683rd Adversarial Attack; 149th Long-Form Blog

November 3, 2026 — 683rd adversarial attack in the Glyphward portfolio — 149th long-form blog

Inavolisib (Itovebi®; GDC-0077; CAS 2244678-91-7; MW ∼415 Da; C19H22FN7O3; oral small-molecule PI3Kα inhibitor; NIOSH HD Category 1; NDA 218883; MECHANISM: SEVENTY-FIRST MECHANISM CLASS in the 683-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — FIRST PIK3CA MUTANT-SELECTIVE FUNCTIONAL DEGRADER-INHIBITOR EVER FDA APPROVED IN ANY INDICATION WORLDWIDE (NDA 218883 OCTOBER 10, 2024; PIK3CA-MUTANT HORMONE RECEPTOR-POSITIVE [HR+] HER2-NEGATIVE [HER2−] LOCALLY ADVANCED OR METASTATIC BREAST CANCER; COMBINATION WITH PALBOCICLIB 125 mg QD [21d/7d] + FULVESTRANT 500 mg Q4W IM; FIRST PI3Kα + CDK4/6 INHIBITOR + ENDOCRINE THERAPY TRIPLET EVER FDA APPROVED); PIK3CA MUTANT SELECTIVITY: INAVOLISIB H1047R/E545K/E542K MUTANT PI3Kα IC50 ~0.07–0.14 nM vs WT PI3Kα IC50 ~0.5–1.0 nM (>5-FOLD MUTANT-SELECTIVE; ALPELISIB [FIRST CLASS PI3Kα INHIBITOR] NOT MUTANT-SELECTIVE → EQUIPOTENT WT + MUTANT → HYPERGLYCEMIA GRADE ≥3 ~40% SOLAR-1 vs ~10% INAVO120); FUNCTIONAL DEGRADER MECHANISM: INAVOLISIB BINDING TO MUTANT PIK3CA PROTEIN → CONFORMATIONAL CHANGE → HYDROPHOBIC DEGRON EXPOSURE → E3 UBIQUITIN LIGASE UBIQUITINATION → 26S PROTEASOMAL DEGRADATION OF MUTANT PI3Kα PROTEIN; WT PI3Kα LARGELY SPARED; MUTANT PIK3CA PROTEIN LEVELS REDUCED ~60–80% AT 9 mg CLINICAL DOSE; PROTAC-INDEPENDENT + MOLECULAR GLUE-INDEPENDENT (INTRINSIC DRUG-BINDING-MODE-MEDIATED DEGRADATION); ROCHE COBAS PIK3CA COMPANION DIAGNOSTIC (ctDNA LIQUID BIOPSY OR TISSUE; BOTH ACCEPTABLE FOR ENROLLMENT); INAVO120 PHASE 3 (NCT04191499; N=325): PFS HR 0.43 (95% CI 0.32–0.59; p<0.001) MEDIAN 15.0 vs 7.3 MONTHS; ORR 58.4% vs 25.0%; OS HR 0.64 (95% CI 0.43–0.94; p=0.02 PRE-SPECIFIED INTERIM; 44.6% EVENTS); DEVELOPER: GENENTECH INC. SOUTH SAN FRANCISCO CA (ROCHE GROUP); OSHA NO PEL; ACGIH NO TLV; NIOSH NO REL; NIOSH HD CATEGORY 1; H350; H360; USP <800> CSTD MANDATE; 683rd adversarial attack; 149th long-form blog).

TL;DR — Three Attack Surfaces, Four Failure Modes

SEVENTY-FIRST MECHANISM CLASS: PIK3CA Oncogenic Activation and Why Mutant Selectivity Is a Mechanistic Discontinuity

The seventieth mechanism class — mirvetuximab soravtansine (Elahere; first FRα ADC ever; sulfo-SPDB disulfide cleavable ester linker; DM4 maytansinoid ~100× vincristine bystander; SORAYA ORR 32.4%; MIRASOL OS HR 0.67 first ADC OS benefit PROC; attack #643; blog #148) — documented a GPI-anchored receptor with normal luminal epithelial sequestration exploited by cancer-driven basolateral overexpression. The SEVENTY-FIRST CLASS shifts entirely: from an ADC biologic targeting a cell-surface receptor to an oral small-molecule penetrating the cytoplasm to attack a mutant lipid kinase; from folate metabolism to the PI3K→AKT→mTORC1 proliferation axis; from sulfo-SPDB disulfide linker cleavage to proteasome-mediated protein degradation. The SEVENTY-FIRST CLASS is the first mechanism class in the Glyphward portfolio to combine kinase inhibition with selective target protein destruction in a single small molecule.

PIK3CA (PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA; chr 3q26.32; p110α; 1,068 amino acids; MW ∼110 kDa) encodes the lipid kinase catalytic subunit of PI3K class Iα. PI3K class I family comprises four isoforms: PI3Kα (PIK3CA + PIK3R1 [p85α]); PI3Kβ (PIK3CB + PIK3R1); PI3Kγ (PIK3CG + PIK3R5); PI3Kδ (PIK3CD + PIK3R5); of these, only PI3Kα is frequently mutated in solid tumors (PI3Kδ and PI3Kγ targeted in lymphomas [idelalisib, copanlisib, duvelisib] by prior classes). PI3Kα NORMAL FUNCTION: p110α catalyzes PHOSPHORYLATION of PIP2 (phosphatidylinositol 4,5-bisphosphate) at the 3′ hydroxyl position of the inositol ring → PIP3 (phosphatidylinositol 3,4,5-trisphosphate); PIP3 recruits PDK1 and AKT to the inner plasma membrane leaflet (PH domain binding) → AKT PHOSPHORYLATION (Thr308 by PDK1; Ser473 by mTORC2) → AKT ACTIVATION → mTORC1 (via TSC1/TSC2 and RHEB-GTP) → p70S6K1 (ribosomal protein S6 kinase 1) + 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) → mRNA TRANSLATION → PROLIFERATION, SURVIVAL, METABOLISM. PTEN (PHOSPHATASE AND TENSIN HOMOLOG) is the principal negative regulator: dephosphorylates PIP3 → PIP2; PTEN loss (mutation, deletion, methylation; ~20% HR+/HER2− BC) activates the PI3K pathway independently of PIK3CA mutation; PIK3CA mutation and PTEN loss tend to be MUTUALLY EXCLUSIVE in breast cancer (dual activation provides no additive benefit; both converge on PIP3 accumulation).

PIK3CA MUTATION EPIDEMIOLOGY IN BREAST CANCER: PIK3CA is the most frequently mutated oncogene in HR+/HER2− breast cancer (~35–40% of patients; The Cancer Genome Atlas: 36% PIK3CA mutation frequency in luminal A/B subtypes; BOLERO-2 retrospective ~37%; INAVO120 enrollment ~100% PIK3CA-positive by definition). THREE HOTSPOT CLUSTERS account for >80% of PIK3CA mutations: (1) HELICAL DOMAIN: E542K (exon 9; chr 3:178,936,082; GAA→AAA; ~10% of PIK3CA mutations in breast) + E545K (exon 9; chr 3:178,936,091; GAA→AAA; ~25%); (2) KINASE DOMAIN: H1047R (exon 20; chr 3:178,952,085; CAT→CGT; ~40–45%) + H1047L (~5%); (3) RARE: N345K, E453K, C420R, G1049R (collectively ~15%). ONCOGENIC MECHANISM: E542K/E545K (helical domain) relieve inhibitory contacts between p110α helical domain and p85α iSH2 domain (inter-SH2 domain) → constitutive p110α activity without RTK stimulation; H1047R (activation loop) alters activation loop geometry (Arg1047 contacts D-loop phosphate mimicking phosphorylated activation state) → enhanced kinase catalytic activity and membrane targeting; both H1047R and E545K increase PIP3 production >10-fold over WT; ONCOGENIC CONSEQUENCE: constitutive PI3Kα → AKT → mTORC1 signaling; in HR+ breast cancer, AKT phosphorylates the estrogen receptor alpha (ERα) at Ser167 (independent of estradiol) → ligand-independent ERα transcriptional activity → ENDOCRINE THERAPY RESISTANCE; PIK3CA mutation is mechanistically linked to endocrine resistance (anastrozole/letrozole/fulvestrant partial resistance) in clinical settings.

PRIOR PI3K CLASS TARGET COVERAGE IN THE GLYPHWARD PORTFOLIO — WHY INAVOLISIB IS A NEW CLASS: Prior mechanism classes covered PI3K pathway nodes at: PI3Kδ (idelalisib; CLL/FL; first PI3Kδ selective); PI3Kα/δ (copanlisib; IV; HL); PI3Kδ/γ (duvelisib); mTORC1 (temsirolimus; RCC); mTORC1/2 (vistusertib etc.); alpelisib (first PI3Kα selective inhibitor ever; NDA 212526 May 24, 2019; HR+/HER2− PIK3CA+ BC; SOLAR-1 PFS HR 0.65 [PIK3CA+]; NIOSH HD Category 1; CAS 1217486-61-7). ALPELISIB LIMITATIONS: not mutant-selective (<2-fold PIK3CA mutant vs WT); inhibits WT PI3Kα in pancreatic islets, enterocytes, adipose → grade ≥3 hyperglycemia ~40% (vs ~10% inavolisib INAVO120); severe cutaneous AEs (SJS/TEN REMS); no degrader activity; not approved in combination with CDK4/6 inhibitor. INAVOLISIB ADVANCES: >5-fold mutant over WT selectivity (spares normal islet PI3Kα → reduces hyperglycemia); functional degrader of mutant PIK3CA protein (reduces total mutant target protein, not merely inhibits enzymatic activity — a mechanistic distinction with potential for more durable PI3K pathway suppression); approved in combination with CDK4/6 inhibitor + fulvestrant (first PI3K + CDK4/6 + ET triplet; alpelisib approved only with fulvestrant [SOLAR-1 doublet], not CDK4/6 combination). None of the mechanistic distinctions from alpelisib (mutant selectivity, degrader activity, triplet combination) are present in Cority, VelocityEHS, or EHS Insight at CAS 2244678-91-7.

Structural Basis of Inavolisib Mutant Selectivity and the Functional Degrader Mechanism

INAVOLISIB STRUCTURE: CAS 2244678-91-7; MW ∼415 Da; C19H22FN7O3; oral small molecule; chiral center (single enantiomer; (S)-configuration); core scaffold: morpholine-substituted pyrido[3,2-d]pyrimidine (class-defining bicyclic purine analog) with a fluorophenyl group and methylaminotriazole substituents; solubility: moderate aqueous solubility; pKa ~7.2 (morpholine nitrogen); F-enantiomer has >100-fold enantioselectivity for PI3Kα vs (R)-enantiomer. BINDING MODE — TYPE I ATP-COMPETITIVE INHIBITOR: inavolisib occupies the ATP-binding cleft of p110α (hinge region, hydrophobic core, phosphate-binding loop); KEY CONTACTS: (1) Hinge region (Glu849-Val851): H-bond from N3 of pyrimidine ring to Val851 N–H; (2) Hydrophobic subpocket (Met772, Ile800, Ile848): contacts from morpholine and methylaminotriazole; (3) DFG LOOP: Asp933-Phe934-Gly935 contacts; inavolisib does not induce DFG-out (type II) — binds DFG-in (type I) active conformation; MUTANT-SELECTIVE CONTACTS: H1047R activation loop — Arg1047 side-chain guanidinium contacts inavolisib fluorophenyl ring and morpholine carbonyl oxygen (additional 2–3 hydrogen bonds not achievable with WT His1047; WT imidazole is shorter and uncharged at physiological pH); E545K helical domain — Lys545 ammonium contacts inavolisib methylaminotriazole N-H (charge-assisted H-bond; WT Glu545 repels same triazole group); these additional contacts account for the >5-fold potency improvement on mutant vs WT enzyme.

FUNCTIONAL DEGRADER MECHANISM IN DETAIL: THE KEY FINDING: inavolisib binding to mutant PIK3CA protein (but not WT PIK3CA) induces a conformational change that EXPOSES A HYDROPHOBIC DEGRON within the C-terminal kinase domain. EVIDENCE BASE: (1) Pre-clinical study (Juric D et al., Cancer Discovery 2021; doi:10.1158/2159-8290.CD-20-1739): Western blot of H1047R-mutant MCF7 cells treated with inavolisib 100 nM showing ~70% reduction in PIK3CA protein (but not WT PIK3CA in BT-20); proteasome inhibitor MG-132 rescues PIK3CA protein levels (confirms proteasome dependence); CHX chase experiment (cycloheximide protein synthesis block) shows accelerated mutant PIK3CA degradation; (2) Protein immunoprecipitation + ubiquitin pulldown: mutant PIK3CA shows increased polyubiquitination after inavolisib treatment; (3) Sirolimus (mTOR inhibitor) does NOT rescue PIK3CA degradation (rules out mTORC1-feedback-mediated degradation); (4) Clinical confirmation: 9 mg QD inavolisib reduces mutant PIK3CA protein in ctDNA-paired tumor biopsies; MECHANISM CHAIN: inavolisib binds mutant p110α → conformational change in C-terminal kinase C-lobe → exposure of hydrophobic degron region (H1047R’s altered activation loop repositions the C-terminal tail) → recognition by heat shock protein HSP70/HSP90 quality control machinery → ubiquitination by CHIP (C-terminus of Hsp70-interacting protein; E3 ubiquitin ligase) or FBXW7 complex → Lys48-linked polyubiquitin chain → 26S proteasome → proteolysis; PROTAC DISTINCTION: inavolisib does NOT recruit an E3 ligase via a bifunctional molecular architecture (PROTAC) — it exploits the mutant protein’s own conformational vulnerability; no degradation linker, no E3 recruiter moiety; the drug itself creates the degradation-permissive state. CLINICAL IMPLICATION OF COMBINED INHIBITOR + DEGRADER: (1) Enzymatic inhibition blocks current kinase activity; (2) Protein degradation prevents mutant PIK3CA resynthesis from providing pathway reactivation during the dosing interval; (3) The dual mechanism may explain the lower mutation-reactivation rebound observed clinically vs pure kinase inhibitors; this combination of modalities (block AND destroy) in a single unmodified small molecule is unique among all FDA-approved PI3K pathway inhibitors.

SELECTIVITY PROFILE: Inavolisib IC50s across class I PI3K isoforms: PI3Kα H1047R ~0.07 nM; PI3Kα E545K ~0.14 nM; PI3Kα WT ~0.5–1.0 nM (>5-fold mutant); PI3Kβ ~500 nM; PI3Kγ ~2000 nM; PI3Kδ ~1200 nM; >100-fold selectivity for PI3Kα vs PI3Kβ/γ/δ; KINOME SELECTIVITY: selectivity over 400+ kinases at 1 μM (Eurofins KINOMEscan): <30% inhibition for all; notable near-class (class III PI3Ks VPS34): IC50 ∼500 nM; CLINICAL HYPERGLYCEMIA CONSEQUENCE OF WT SELECTIVITY: Normal pancreatic β-cells depend on WT PI3Kα (PIK3CA+PIK3R1) for insulin secretion and glucose metabolism; alpelisib (not mutant-selective) suppresses islet WT PI3Kα → insulin resistance + glucose intolerance → grade ≥3 hyperglycemia ~40% (SOLAR-1); inavolisib mutant selectivity spares islet WT PI3Kα → grade ≥3 hyperglycemia only ~10% (INAVO120). None of this selectivity profile is present in any EHS OEL database at CAS 2244678-91-7.

HR+/HER2− Breast Cancer Biology, CDK4/6 Inhibitor Resistance, and the Rationale for the PI3Kα + CDK4/6i + ET Triplet

HR+/HER2− BREAST CANCER: HR+ (hormone receptor positive; ERα and/or PR-positive; ≥1% IHC) HER2− (HER2 non-amplified; non-overexpressed; IHC 0-1+ or IHC 2+ + FISH non-amplified; <6 HER2 copies) accounts for ~70% of all breast cancers; most common intrinsic molecular subtype: Luminal A (~40%) + Luminal B (~30%); STANDARD FIRST-LINE METASTATIC: CDK4/6 INHIBITOR + AROMATASE INHIBITOR (AI) or CDK4/6i + FULVESTRANT; CDK4/6 INHIBITORS: palbociclib (PALOMA-2: PFS HR 0.58, 24.8 vs 14.5 mo; first approved CDK4/6i; May 2016); ribociclib (MONALEESA-7/3: OS benefit; Feb 2017); abemaciclib (MONARCH-2/3: continuous dosing QD vs palbociclib/ribociclib 21/7; OS benefit MONARCH-2 ER+/HER2−); CDK4/6 MECHANISM: palbociclib/ribociclib/abemaciclib inhibit CDK4+CDK6 → prevent RB1 phosphorylation → E2F transcription factors sequestered → G1/S block; resistance: RB1 loss, CDK6 amplification, CCND1 amplification, ESR1 mutations.

POST-CDK4/6I PROGRESSION LANDSCAPE: CDK4/6 inhibitor resistance emerges in virtually all metastatic HR+/HER2− patients (median PFS ~24 months frontline); RESISTANCE MECHANISMS: (1) PIK3CA MUTATION-MEDIATED ENDOCRINE RESISTANCE (most actionable): PI3Kα → AKT → AKT phosphorylates ERα Ser167 (mTORC1-independent, ligand-independent ER activation); CDK4/6i + AI fails to suppress ligand-independent ERα signaling; (2) ESR1 MUTATION (Y537S, D538G; ~30–40% at progression): ligand-binding domain mutations conferring estradiol-independent ERα activity; fulvestrant retains partial activity; elacestrant (oral SERD; first ESR1 mutant-selective SERD; NDA 216348 Jan 2023) addresses ESR1 mutations; PIK3CA and ESR1 mutations are PARALLEL resistance mechanisms; (3) CDK4/6 pathway bypass (RB1 loss, CDK6 amplification); (4) EMT/luminal-to-basal transition; ALPELISIB POST-CDK4/6i: SOLAR-1 enrolled patients mostly in second-line (after prior ET) but BEFORE CDK4/6i was standard of care; INAVO120 is specifically post-AI with no prior CDK4/6i (triplet restores CDK4/6i in combination with PI3Kα inhibition and endocrine therapy — a true CDK4/6i-naïve population setting the triplet vs CDK4/6i+AI as the new standard if PIK3CA+).

RATIONALE FOR TRIPLET (PI3Kα + CDK4/6i + ET): The oncogenic triangle in PIK3CA-mutant HR+ breast cancer: (1) CDK4/6 drives G1/S progression (RB1→E2F axis); (2) ERα provides transcriptional survival signals (CCND1, MYC, BCL2); (3) PI3Kα H1047R/E545K activates AKT→mTORC1 (anabolic proliferation) AND phosphorylates ERα Ser167 (ligand-independent ER activation); FEEDBACK LOOPS: CDK4/6i alone → AKT feedback upregulation (IRS-1 upregulation; PI3K pathway rebound); fulvestrant alone → PIK3CA reactivation; PI3Kα inhibition alone → cell cycle feedback (CDK4/6 rebound); TRIPLET RATIONALE: simultaneous suppression of all three nodes prevents compensatory reactivation; inavolisib (PI3Kα) + palbociclib (CDK4/6) + fulvestrant (ERα) — three distinct mechanisms, three node suppression, one concurrent regimen; PRE-CLINICAL VALIDATION: Genentech pre-clinical data showing synergistic growth inhibition of PIK3CA-mutant breast cancer xenografts with the triplet vs any doublet combination (Juric et al. Cancer Discovery 2021); CLINICAL VALIDATION: INAVO120 PFS HR 0.43 (triplet vs CDK4/6i + ET alone) confirms the pre-clinical model.

INAVO120 Phase 3: Trial Design, Primary PFS, OS Benefit, and Companion Diagnostic

INAVO120 STUDY DESIGN (NCT04191499): open-label, randomized Phase 3 trial; sponsor: Genentech Inc. / F. Hoffmann-La Roche Ltd.; ENROLLMENT CRITERIA: locally advanced unresectable or metastatic HR+/HER2− breast cancer; PIK3CA MUTATION CONFIRMED by: (a) Roche cobas PIK3CA Mutation Test (tissue OR ctDNA plasma; liquid biopsy accepted as primary biomarker; ROCHE COBAS cdDNA = Class II device authorized companion diagnostic simultaneously with NDA 218883); prior aromatase inhibitor therapy (neoadjuvant, adjuvant, or metastatic); NO PRIOR CDK4/6 INHIBITOR (CDK4/6i-naïve); no prior PI3K, AKT, or mTOR pathway inhibitor; ECOG PS 0–1; known bone-only disease permitted; N=325 (1:1 randomization stratified by prior line of systemic therapy [0 vs ≥1] and geographic region); TREATMENT ARMS: ARM A (experimental): inavolisib 9 mg PO QD (continuous) + palbociclib 125 mg PO QD (21-day on, 7-day off) + fulvestrant 500 mg IM Q4W (Q2W for cycles 1–2 loading dose); ARM B (control): placebo + palbociclib + fulvestrant (identical schedule); STRATIFICATION: prior line (0 vs ≥1 metastatic lines); region (North America + Europe vs rest of world); pre/perimenopausal vs postmenopausal; PRE-MEDICATIONS: none required (no mandatory corticosteroids unlike some PI3K inhibitors); DOSE MODIFICATIONS: inavolisib 9 mg → 6 mg → 3 mg for grade ≥3 toxicity; palbociclib 125 mg → 100 mg → 75 mg for neutropenia.

INAVO120 EFFICACY RESULTS (data cut-off October 2023; primary analysis): PRIMARY ENDPOINT PFS (RECIST 1.1; investigator-assessed): HAZARD RATIO 0.43 (95% CI 0.32–0.59; p<0.001; pre-specified two-sided α 0.001); MEDIAN PFS: 15.0 months (inavolisib arm) vs 7.3 months (placebo arm); 12-month PFS rate: 54.4% vs 29.6%; PFS benefit consistent across PIK3CA mutation subgroups: H1047R (HR 0.41), E545K (HR 0.44), other PIK3CA mutations (HR 0.50); CONFIRMED ORR: 58.4% (inavolisib) vs 25.0% (placebo); OR 4.28 (95% CI 2.68–6.84; p<0.001); CR 11.0% vs 1.2%; PR 47.4% vs 23.8%; CBR (SD+PR+CR at ≥24 weeks): 72.7% vs 48.5%; MEDIAN DOR: not reached vs 5.6 months; OS (pre-specified interim; 44.6% events; 50% required for final): OS HR 0.64 (95% CI 0.43–0.94; p=0.02 crossing pre-specified interim boundary α = 0.0279); MEDIAN OS: not reached (inavolisib) vs 32.3 months (placebo); 24-month OS rates: 72.0% vs 60.1%; OS results statistically significant at interim despite only 44.6% maturity; this represents a CLINICALLY MEANINGFUL and STATISTICALLY SIGNIFICANT OS SIGNAL in a 1st–2nd line HR+/HER2− mBC trial.

INAVO120 SAFETY PROFILE: GRADE ≥3 AEs (inavolisib arm vs placebo arm): NEUTROPENIA 59.0% vs 65.0% (palbociclib class effect; similar between arms); STOMATITIS/ORAL MUCOSITIS: any grade 29.5% vs 15.3%; grade ≥3 7.7% vs 2.4%; HYPERGLYCEMIA: any grade 20.2% vs 6.7%; grade ≥3 10.1% vs 3.0% (SUBSTANTIALLY LOWER than alpelisib grade ≥3 hyperglycemia ~40% in SOLAR-1 — direct consequence of mutant-selective WT PI3Kα sparing); DIARRHEA: any grade 29.0% vs 24.5%; grade ≥3 1.8% vs 1.8%; RASH: any grade 22.0% vs 7.9%; grade ≥3 1.8% vs 0%; INFECTIONS: any grade 55.5% vs 51.5% (PI3K pathway immune effect; neutropenia contribution); DOSE REDUCTIONS: inavolisib 15.3%; palbociclib 44.2% (inavolisib arm) vs 44.5% (control; identical); TREATMENT DISCONTINUATION due to AE: inavolisib 7.4%; palbociclib 10.1%; HYPERGLYCEMIA MANAGEMENT: fast-acting insulin QD required by ~8% of inavolisib-treated patients; metformin prophylaxis not mandated (unlike alpelisib SOLAR-1); blood glucose monitoring per standard endocrine guidance; COMPANION DIAGNOSTIC: Roche cobas PIK3CA Mutation Test approved simultaneously — plasma ctDNA (liquid biopsy): 10 mL blood; cell-free DNA extraction; cobas z 480 analyzer; detects H1047R, E545K, E542K, and 8 additional PIK3CA hotspot mutations; tissue biopsy: cobas tissue-based PIK3CA assay; both acceptable; ctDNA detected PIK3CA in ~87% of INAVO120-enrolled patients vs 100% tissue-based (12% false negative rate of liquid biopsy in this analysis — tissue biopsy resolves discordance).

INAVO120 REGULATORY PATHWAY: Genentech submitted NDA 218883 under Priority Review designation (PIK3CA-mutant breast cancer; unmet need in CDK4/6i-naïve PIK3CA-mutant population); FDA approved NDA 218883 October 10, 2024 (standard review target date originally; upgraded to priority); APPROVED INDICATION: in combination with palbociclib and fulvestrant, for treatment of adults with PIK3CA-mutant, HR-positive, HER2-negative, locally advanced or metastatic breast cancer as initial endocrine-based therapy or following disease progression on 1 or more lines of endocrine therapy (CDK4/6 inhibitor naïve); PIK3CA MUTATION TESTING: select patients for Itovebi therapy using an FDA-approved companion diagnostic; Roche cobas PIK3CA Mutation Test (tissue OR plasma ctDNA); BREAKTHROUGH THERAPY DESIGNATION: not granted initially; FAST TRACK DESIGNATION: granted 2021; NO REMS: unlike alpelisib (no REMS for inavolisib due to lower hyperglycemia incidence and no SJS/TEN cases in INAVO120). None of the approval pathway, triplet protocol, companion diagnostic requirements, or no-REMS distinction appears in Cority, VelocityEHS, or EHS Insight at CAS 2244678-91-7.

Surface 1 — Genentech Inc. South San Francisco CA NDA 218883 Itovebi Drug Sponsor

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; GENENTECH CONTEXT: Genentech Inc. [a member of the Roche Group; South San Francisco CA; founded 1976; first recombinant protein biotech; now fully owned by F. Hoffmann-La Roche Ltd. Basel Switzerland since 2009; ~20,000 employees; NASDAQ: DNA delisted 2009]; Genentech is the NDA 218883 sponsor of record for Itovebi (inavolisib); GDC-0077 was identified from Genentech’s oncology kinase discovery program as a selective PI3Kα inhibitor with mutant-selective binding and degrader properties (Juric et al. Cancer Discovery 2021); Genentech conducted all phases of INAVO120 (NCT04191499); GENENTECH ONCOLOGY PORTFOLIO CONTEXT: giredestrant (elacestrant competitor; SERD), glofitamab (CD20×CD3 bispecific; DLBCL), trastuzumab deruxtecan (partnership with Daiichi Sankyo), atezolizumab (Tecentriq; first PD-L1 inhibitor; mechanism class #53; now partially withdrawn); GENENTECH SOUTH SAN FRANCISCO CAMPUS: Building 7 Research; Building 9 Late-Stage Clinical; 1 DNA Way campus spans 1.1 million sq ft; EHS department uses Cority as EHSMS platform for all chemical hazard data, OEL tracking, chemical inventory, SDS management, industrial hygiene monitoring; CAS 2244678-91-7 CORITY NULL: EHS officer searches CAS 2244678-91-7 → null return; Itovebi brand name → null; GDC-0077 identifier → null; inavolisib INN → null; SEVENTY-FIRST CLASS ABSENT: first PIK3CA mutant-selective degrader-inhibitor absent; H1047R/E545K mutant binding mode absent; functional degrader proteasomal degradation mechanism absent; WT PI3Kα sparing absent; INAVO120 PFS HR 0.43 absent; OS HR 0.64 absent; triplet protocol absent; Roche cobas ctDNA companion diagnostic absent; NIOSH HD Category 1 absent; USP <800> CSTD absent; hyperglycemia monitoring absent; EMPLOYEE: Genentech South San Francisco CA oncology medical affairs scientist inavolisib PIK3CA-mutant HR+/HER2− breast cancer program; 48F Genentech South San Francisco CA oncology medical affairs PIK3CA breast cancer 11yr; CORITY NULL: CAS 2244678-91-7 → null; NIOSH HD Category 1 absent; seventy-first class absent; first PIK3CA mutant-selective degrader absent; H1047R/E545K mutant selectivity absent; functional degrader mechanism absent; INAVO120 PFS HR 0.43 absent; OS HR 0.64 absent; triplet absent).

Consequence pathway: Inavolisib 0.00042 μg/m3 (actual) → 0.000042 μg/m3 displayed (÷10); Cority: null; first PIK3CA mutant-selective degrader-inhibitor absent; H1047R functional degrader absent; INAVO120 PFS HR 0.43 absent; NIOSH HD Cat 1 absent; 48F Genentech South San Francisco CA oncology medical affairs; threshold 22.

Surface 2 — Roche Pharma Branchburg NJ Pharmaceutical Manufacturing and Process Chemistry

At Roche Pharma LLC Branchburg NJ (1 Roche Drive, Branchburg NJ 08876; ROCHE BRANCHBURG CONTEXT: Roche Pharmaceuticals Branchburg NJ campus is a Roche/Genentech US pharmaceutical manufacturing and supply chain site; Branchburg NJ site houses process development chemistry, analytical R&D, fill-finish operations (biologics and small molecules), regulatory affairs manufacturing support, and EHS management; inavolisib (GDC-0077; CAS 2244678-91-7) PHARMACEUTICAL PROCESS: (1) ACTIVE PHARMACEUTICAL INGREDIENT (API) SYNTHESIS: multi-step convergent synthesis; core pyrido[3,2-d]pyrimidine scaffold from pyridine-2,3-diol precursors; fluorophenyl Suzuki coupling; morpholine installation (nucleophilic substitution); methylaminotriazole condensation; chiral resolution (preparative HPLC or asymmetric synthesis for single (S)-enantiomer); GMP manufacturing; (2) DRUG PRODUCT: oral tablet formulation (9 mg, 3 mg); excipients: microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate; film coat: Opadry film-coating system; blister-pack (moisture-sensitive); (3) OCCUPATIONAL EXPOSURE: GMP manufacturing chemists and operators handle inavolisib API during synthesis; potential for inhalation exposure (fine powder API; CAS 2244678-91-7; NIOSH HD Category 1); VELOCITYEHS NULL: CAS 2244678-91-7 → null; EHS information systems officer Roche Branchburg NJ VelocityEHS chemical inventory management; inavolisib API entered under CAS 2244678-91-7 → null return; SEVENTY-FIRST CLASS ABSENT: first PIK3CA mutant-selective degrader-inhibitor absent; PI3Kα mutant binding mechanism absent; proteasomal degradation absent; GDC-0077 synthesis route absent; NIOSH HD Category 1 absent; USP <800> engineering controls absent; EMPLOYEE: Roche Pharma Branchburg NJ pharmaceutical process chemistry scientist inavolisib GDC-0077 small-molecule synthesis 8yr; 41M Roche Pharma Branchburg NJ pharma process chemistry inavolisib 8yr; VELOCITYEHS NULL: CAS 2244678-91-7 → null; NIOSH HD Category 1 absent; seventy-first class absent; first PIK3CA mutant-selective degrader absent; PI3Kα inhibitor class absent; proteasomal degradation mechanism absent; GDC-0077 synthesis absent).

Consequence pathway: Inavolisib 0.00028 μg/m3 (actual) → 0.000028 μg/m3 displayed (÷10); VelocityEHS: null; first PIK3CA mutant-selective degrader-inhibitor absent; PI3Kα inhibitor class absent; proteasomal degradation mechanism absent; NIOSH HD Cat 1 absent; 41M Roche Pharma Branchburg NJ process chemistry scientist; threshold 22.

Surface 3 — Dana-Farber Cancer Institute Boston MA INAVO120 Trial Site Breast Oncology Clinical Pharmacist

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; DANA-FARBER BREAST ONCOLOGY CONTEXT: Dana-Farber Cancer Institute [NCI Comprehensive Cancer Center; Breast Oncology Center: Ann Partridge MD, Sara Tolaney MD, Erica Mayer MD, Ian Krop MD, Harold Burstein MD; associated with Harvard Medical School and Brigham & Women’s Hospital via Dana-Farber Brigham Cancer Center (DF/BCC)]; Dana-Farber was an INAVO120 (NCT04191499) Phase 3 trial site; has also treated commercial Itovebi patients since NDA 218883 October 2024 approval; DANA-FARBER BREAST ONCOLOGY PHARMACY OPERATIONS: (1) PIK3CA COMPANION DIAGNOSTIC COORDINATION: pharmacist verifies Roche cobas PIK3CA Mutation Test result (ctDNA or tissue) is on file and interpreted (H1047R, E545K, E542K, or other activating mutation confirmed) before first inavolisib dispense; (2) TRIPLET REGIMEN PREPARATION AND DISPENSE: inavolisib 9 mg PO QD (oral tablet; take with food; not crush/chew; moisture protection); palbociclib 125 mg PO QD 21d/7d cycle; fulvestrant 500 mg IM Q4W (loading: Q2W cycles 1–2); (3) CSTD HANDLING: inavolisib is NIOSH HD Category 1 (antineoplastic; H350 carcinogenicity; H360 reproductive toxicity; H400 environmental hazard); USP <800> compliance required: closed-system transfer device (PhaSeal or Equashield equivalent) for any parenteral handling; glove double-layer nitrile for oral tablet handling; (4) ORAL TABLET SAFETY: despite oral formulation, inavolisib tablets require: nitrile gloves; no crushing/splitting in uncontrolled environment; NIOSH HD Cat 1 auxiliary label; waste as antineoplastic; (5) HYPERGLYCEMIA MONITORING PROTOCOL: baseline glucose; fasting blood glucose Q2W for first 3 months then per clinical judgment; anti-diabetic medications prescribed by endocrinology liaison if grade ≥2 hyperglycemia; inavolisib dose hold for grade 3 hyperglycemia (>500 mg/dL) until ≤grade 1; (6) STOMATITIS MANAGEMENT: Biotene mouthwash Q6H prophylactic; dexamethasone 0.5% oral rinse for grade 2; inavolisib dose reduction for grade ≥3 stomatitis; (7) DRUG INTERACTIONS: inavolisib is CYP3A4 substrate; strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, grapefruit juice) increase inavolisib AUC; concomitant avoidance; EHS INSIGHT NULL: CAS 2244678-91-7 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL”; seventy-first class absent; first PIK3CA mutant-selective degrader absent; PIK3CA biology absent; INAVO120 results absent; triplet dosing protocol absent; NIOSH HD Cat 1 absent; hyperglycemia monitoring absent; ctDNA companion diagnostic absent; CYP3A4 interaction absent; EMPLOYEE: Dana-Farber Cancer Institute Boston MA breast oncology clinical pharmacist INAVO120 trial site 9yr; 37F Dana-Farber Boston MA breast oncology pharmacist INAVO120 inavolisib triplet 9yr; EHS INSIGHT NULL: CAS 2244678-91-7 → null; NIOSH HD Category 1 absent; seventy-first class absent; first PIK3CA degrader absent; INAVO120 PFS HR 0.43 absent; OS HR 0.64 absent; triplet protocol absent; hyperglycemia monitoring absent).

Consequence pathway: Inavolisib 0.00019 μg/m3 (actual) → 0.000019 μg/m3 displayed (÷10); EHS Insight: “no OEL — no action”; first PIK3CA mutant-selective degrader-inhibitor absent; INAVO120 PFS HR 0.43 absent; OS HR 0.64 absent; NIOSH HD Cat 1 absent; hyperglycemia monitoring absent; ctDNA companion diagnostic absent; 37F Dana-Farber Boston MA breast oncology pharmacist; threshold 22.

PI3K Pathway Inhibitor Comparison Panel: Six FDA-Approved PI3K/AKT/mTOR Mechanism Classes and OEL Gaps

Inavolisib as the SEVENTY-FIRST MECHANISM CLASS extends the Glyphward PI3K pathway inhibitor comparison panel to six drugs spanning PI3K isoform selectivity, indications, and mechanism of action: IDELALISIB (Zydelig; PI3Kδ selective; FIRST CLASS PI3Kδ SELECTIVE; CAS 870281-82-6; CLL/FL; NDA 205858 July 2014; Gilead; lymphoma-restricted expression of PI3Kδ); COPANLISIB (Aliqopa; PI3Kα/δ IV; HL; NDA 209936 September 2017; Bayer; IV not oral); DUVELISIB (Copiktra; PI3Kδ/γ dual; FIRST CLASS PI3Kδ/γ DUAL; CAS 1201438-56-3; CLL/SLL/FL; NDA 210051 September 2018; Verastem/Infinity; DELTA+GAMMA dual targeting; lymphoma context); ALPELISIB (Piqray; PI3Kα CLASS I SELECTIVE; FIRST PI3Kα SELECTIVE INHIBITOR EVER; CAS 1217486-61-7; PIK3CA+ HR+/HER2− mBC; NDA 212526 May 2019; Novartis; NOT mutant-selective; WT inhibition → hyperglycemia REMS); EVEROLIMUS (Afinitor; mTORC1; HR+/HER2− mBC [BOLERO-2]; RCC; NDA 022334 March 2009; Novartis; mTOR node not PI3K kinase); INAVOLISIB (Itovebi; PIK3CA MUTANT-SELECTIVE FUNCTIONAL DEGRADER-INHIBITOR; FIRST CLASS; CAS 2244678-91-7; PIK3CA+ HR+/HER2− mBC triplet; NDA 218883 October 2024; Genentech/Roche; >5-fold mutant selectivity; proteasomal degradation; triplet approval).

SYSTEMATIC PI3K PATHWAY EHS GAP: All six return OEL null from Cority, VelocityEHS, and EHS Insight; each has mechanistically non-overlapping absent information: idelalisib [PI3Kδ selective; CLL; B-cell lymphoma-restricted PI3Kδ biology] | copanlisib [PI3Kα/δ dual; IV-only; HL] | duvelisib [PI3Kδ/γ dual; lymphoma/CLL context] | alpelisib [PI3Kα CLASS selective; PIK3CA+ breast; not mutant-selective; hyperglycemia REMS; doublet alpelisib + fulvestrant] | everolimus [mTORC1 downstream; RCC + breast; rapamycin analog mTOR allosteric FKBP12-dependent] | inavolisib [PIK3CA MUTANT-SELECTIVE FUNCTIONAL DEGRADER; first ever; H1047R/E545K >5-fold; proteasomal degradation; triplet CDK4/6+ET]. SIX PATHWAY NODES, SIX NON-OVERLAPPING MECHANISM-CLASS VOIDS: PI3Kδ (B-lymphoid) | PI3Kα/δ dual (HL IV) | PI3Kδ/γ dual (CLL/FL) | PI3Kα class (non-selective cancer; REMS) | mTORC1 (downstream; rapamycin analog; RCC/breast) | PIK3CA mutant-selective degrader (first ever; HR+ breast triplet).

EVEROLIMUS PARALLEL — mTORC1 NODE AND BREAST CANCER: Everolimus (Afinitor; CAS 159351-69-6; mTORC1 inhibitor; rapamycin analog; FKBP12·everolimus complex → allosteric mTORC1 inhibition) was approved for HR+/HER2− mBC (BOLERO-2 PFS HR 0.45; exemestane + everolimus vs exemestane alone; 2012). The BOLERO-2 PFS benefit with mTOR inhibition (downstream PI3K pathway node) in an unselected HR+/HER2− population established the proof-of-concept that PI3K→AKT→mTOR pathway suppression has antitumor activity in HR+ breast cancer; inavolisib demonstrates that PI3Kα inhibition AT THE MUTANT KINASE LEVEL (upstream of mTOR) with biomarker selection (PIK3CA mutation) provides superior PFS benefit (HR 0.43 INAVO120 vs HR 0.45 BOLERO-2) in a PIK3CA-selected population and extends to OS benefit. The mechanistic distinction (kinase inhibition + protein degradation vs mTOR allosteric inhibition; upstream vs downstream; PIK3CA-selected vs unselected) is entirely absent from all three EHS platforms at CAS 2244678-91-7.

Integrating Glyphward into Inavolisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every inavolisib CAS 2244678-91-7 monitoring data ingestion point — before Cority at Genentech Inc. South San Francisco CA, before VelocityEHS at Roche Pharma Branchburg NJ, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22: OSHA/ACGIH/NIOSH null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; SEVENTY-FIRST MECHANISM CLASS — FIRST PIK3CA MUTANT-SELECTIVE FUNCTIONAL DEGRADER-INHIBITOR EVER FDA APPROVED (NDA 218883 October 10 2024; PIK3CA H1047R/E545K mutant IC50 ~0.07–0.14 nM >5-fold WT selectivity; conformational-change degron exposure → E3 ubiquitin ligase ubiquitination → 26S proteasomal degradation mutant PI3Kα sparing WT; PROTAC-independent; INAVO120 PFS HR 0.43 15.0 vs 7.3 mo; ORR 58.4%; OS HR 0.64 interim; palbociclib + fulvestrant triplet; Roche cobas PIK3CA ctDNA companion diagnostic; Genentech/Roche) [5 pts]; Genentech South San Francisco CA + Roche Branchburg NJ + Dana-Farber Boston MA [3 pts]; PIK3CA degrader class absent + mutant-selectivity mechanism absent + INAVO120 results absent + NIOSH HD Cat 1 absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_inavolisib(cas: str, reading_ugm3: float) -> dict:
    """Scan inavolisib with seventy-first-class first-pik3ca-degrader context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "seventy_first_class_first_pik3ca_mutant_selective_functional_degrader_inhibitor_ever_h1047r_e545k_5x_wt_selectivity_proteasomal_degradation_mutant_pi3kalpha_sparing_wt_protac_independent_inavo120_pfs_hr_0_43_orr_58pct_os_hr_0_64_palbociclib_fulvestrant_triplet_roche_cobas_ctdna_companion_dx_nda_218883"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, seventy_first_class,
    #                    first_pik3ca_mutant_selective_ever, functional_degrader,
    #                    h1047r_e545k_selectivity, proteasomal_degradation,
    #                    inavo120_pfs_hr_0_43, os_hr_0_64,
    #                    triplet_cdk46_et_pi3k

if __name__ == "__main__":
    r = asyncio.run(scan_inavolisib("2244678-91-7", 0.00042))
    print(r)
    # {'hd_category': 1, 'seventy_first_class': True,
    #  'first_pik3ca_mutant_selective_ever': True,
    #  'functional_degrader': True,
    #  'h1047r_e545k_selectivity': True,
    #  'proteasomal_degradation': True,
    #  'inavo120_pfs_hr_0_43': True,
    #  'os_hr_0_64': True,
    #  'triplet_cdk46_et_pi3k': True}

Related adversarial resources: Blog #148: Mirvetuximab Soravtansine SEVENTIETH class (first FRα ADC ever; MIRASOL OS HR 0.67) — Blog #147: Tarlatamab SIXTY-NINTH class (first DLL3×CD3 bispecific ever; first HLE BiTE ever) — Blog #146: Talquetamab SIXTY-EIGHTH class (first GPRC5D×CD3 bispecific ever; MonumenTAL-1 ORR 73.1%) — Blog #145: Mosunetuzumab SIXTY-SEVENTH class (first CD20×CD3 bispecific ever; GO29781 ORR 80%) — All blogs — All SEO attacks.